Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03737643

Recruitment Status : Active, not recruiting

First Posted : November 9, 2018

Last Update Posted : April 21, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

European Network of Gynaecological Oncological Trial Groups (ENGOT)

GOG Foundation, Inc. (GOG Foundation)

Myriad Genetic Laboratories, Inc.

Information provided by (Responsible Party):

AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	June 23, 2023
Estimated Study Completion Date :	May 25, 2028

To Top